Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel S Merseburger

Showing results (251-260 of 323) with videos related to

Pageof 33
Sort By:
Nuclear Medicine and Molecular Imaging|December 16, 2017
<sup>68</sup>Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate CancerChristoph-Alexander J von Klot, Axel S Merseburger, Alena Böker, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Journal of Proteomics|December 31, 2013
Discovery and validation of urinary biomarkers for detection of renal cell carcinomaMaria Frantzi, Jochen Metzger, Rosamonde E Banks, et al.
Oncotarget|October 21, 2017
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic interventionAgnieszka Latosinska, Marika Mokou, Manousos Makridakis, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Oncology Reports|December 7, 2002
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissuesAxel S Merseburger, Markus A Kuczyk, Jurgen Serth, et al.
Critical Reviews in Oncology/Hematology|December 13, 2021
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomesEkaterina Laukhtina, Reza Sari Motlagh, Keiichiro Mori, et al.
Molecular Cancer Therapeutics|February 22, 2019
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder CancerGeorgios Kallifatidis, Diandra K Smith, Daley S Morera, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
World Journal of Urology|March 3, 2023
Radiomics vs radiologist in prostate cancer. Results from a systematic reviewGiuseppe Chiacchio, Daniele Castellani, Carlotta Nedbal, et al.
Pageof 33

Showing results (251-260 of 323) with videos related to

Sort By:
Pageof 33
Nuclear Medicine and Molecular Imaging|December 16, 2017
<sup>68</sup>Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate CancerChristoph-Alexander J von Klot, Axel S Merseburger, Alena Böker, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Journal of Proteomics|December 31, 2013
Discovery and validation of urinary biomarkers for detection of renal cell carcinomaMaria Frantzi, Jochen Metzger, Rosamonde E Banks, et al.
Oncotarget|October 21, 2017
Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic interventionAgnieszka Latosinska, Marika Mokou, Manousos Makridakis, et al.
European Urology Oncology|September 30, 2025
Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITANAlejo Rodriguez-Vida, Angel Borque, Fernando Lopez-Campos, et al.
Oncology Reports|December 7, 2002
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissuesAxel S Merseburger, Markus A Kuczyk, Jurgen Serth, et al.
Critical Reviews in Oncology/Hematology|December 13, 2021
Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomesEkaterina Laukhtina, Reza Sari Motlagh, Keiichiro Mori, et al.
Molecular Cancer Therapeutics|February 22, 2019
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder CancerGeorgios Kallifatidis, Diandra K Smith, Daley S Morera, et al.
The Journal of Urology|April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World PracticeAxel S Merseburger, Daniel Castellano, Thomas Powles, et al.
World Journal of Urology|March 3, 2023
Radiomics vs radiologist in prostate cancer. Results from a systematic reviewGiuseppe Chiacchio, Daniele Castellani, Carlotta Nedbal, et al.
Pageof 33